Current Report Filing (8-k)
14 Giugno 2016 - 10:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: June 14, 2016
(Date of earliest event reported)
BIOPHARMX CORPORATION
(Exact Name of Registrant as Specified in
Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-37411
|
|
59-3843182
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
1098 Hamilton Court
Menlo Park, California
|
|
94025
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(650) 889-5020
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02. Results of Operations
and Financial Condition
On June 14, 2016, BioPharmX Corporation
(“
Company
”) issued a press release announcing its financial results and certain other information for
the quarterly period ended April 30, 2016. A copy of the press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K.
The information in this Item 2.02,
including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section
or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02
and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document
filed by the Company with the Securities and Exchange Commission, whether made before or after the date of this Current Report
on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K
generally), except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press release issued by BioPharmX Corporation regarding its financial results for the quarterly period ended April 30, 2016, dated June 14, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOPHARMX CORPORATION
|
|
|
|
|
|
|
Date: June 14, 2016
|
By:
|
/s/
greg kitchener
|
|
|
Name:
|
Greg Kitchener
|
|
|
Title:
|
Chief Financial Officer
|
|
|
|
(Principal Financial Officer and Principal Accounting Officer)
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press release issued by BioPharmX Corporation regarding its financial results for the quarterly period ended April 30, 2016, dated June 14, 2016.
|
Grafico Azioni BioPharmX (AMEX:BPMX)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni BioPharmX (AMEX:BPMX)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a BioPharmX Corporation (Borsa Americana (AMEX)): 0 articoli recenti
Più Biopharmx Corp Articoli Notizie